title: Tension pneumocephalus after administration of two 0.25 mg cabergoline tablets in MEN1-related macroprolactinoma.
authors.affiliation: Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Nanba
authors.forename: Takeshi
authors.initials: T
authors.lastname: Usui
authors.forename: Takuya
authors.initials: T
authors.lastname: Nakakuki
authors.forename: Akira
authors.initials: A
authors.lastname: Shimatsu
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077465:Cabergoline; D004873:Ergolines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D018761:Multiple Endocrine Neoplasia Type 1 / Q000150:complications*; D011007:Pneumocephalus / Q000139:chemically induced*; D015175:Prolactinoma / Q000188:drug therapy*; D013607:Tablets
chemical_list: D000970:Antineoplastic Agents; D004873:Ergolines; D013607:Tablets; D000077465:Cabergoline